By: IPP Bureau
Last updated : September 29, 2025 4:19 pm
Global pharma major Lupin Limited (Lupin) announced that its wholly owned subsidiary, Nanomi B.V. (Nanomi), has signed a definitive agreement to acquire VISUfarma B.V. (VISUfarma), a portfolio company of global healthcare specialist investor GHO Capital Partners (GHO).
The acquisition of VISUfarma, with its broad portfolio of innovative eye health products and established commercial infrastructure, aligns with Lupin’s strategy to expand its European presence and advance its global specialty franchise.
By integrating VISUfarma’s established commercial operations, Lupin will strengthen its position in the fast-growing ophthalmology market. The sector is experiencing significant expansion driven by an aging population, the rising incidence of diabetes-related eye complications, and increasing awareness of preventive eye care.
VISUfarma’s operations across Italy, the UK, Spain, Germany, and France will provide Lupin with direct market access and business diversification in key European regions. Its broad portfolio of more than 60 branded ophthalmology products creates opportunities to accelerate Lupin’s specialty segment growth in Europe and beyond.
Vinita Gupta, CEO of Lupin, said: “We are delighted to welcome VISUfarma into the Lupin family. This acquisition strengthens our commitment to delivering innovative medicines to the patients and communities we serve. Beyond being immediately accretive, it broadens our presence in Europe and significantly enhances our specialty franchise in ophthalmology.”
With the integration of VISUfarma, Lupin will offer a comprehensive portfolio of products across therapeutic areas including dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and nutraceuticals prescribed by ophthalmologists.
Lupin will finance the acquisition with existing cash on its balance sheet. The transaction, expected to close by the end of 2025 subject to customary closing conditions, is projected to be accretive to Lupin’s growth and margin profile.
Andrea Ponti, Managing Partner, and Mike Turner, Partner at GHO Capital, commented: “Working closely with the VISUfarma management team, GHO Capital has transformed the company from a domestic Italian ophthalmic player into a pan-European business with established operations across key markets, a robust product portfolio covering the main front- and back-of-the-eye disease areas, and the infrastructure to support its continued growth. We are pleased to have found a partner in Lupin to take VISUfarma to the next stage and build a truly global ophthalmology franchise.”
Paolo Cioccetti, CEO Italy, VISUfarma, added: “Joining Lupin marks an exciting new chapter for VISUfarma. As part of Lupin’s ophthalmology operations, we will build a global ophthalmology franchise with a shared commitment to advancing eye care and improving patient outcomes. We are grateful to GHO Capital for their support and strategic guidance, which have been instrumental in transforming VISUfarma into a pan-European leader in ophthalmology pharmaceuticals.”